GP
HZNP

Girard Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Girard Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$1K – 943
2018
Q3 		$1K Buy
+100
New +$1.9K ﹤0.01% 934

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Girard Partners's HZNP Position: Q4 2018 in Review

Girard Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2018, closing a stake of 100 shares — an estimated $1K sold.

Girard Partners first reported a position in HZNP in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 239 funds tracked by Wall St. Rank hold HZNP as of Q4 2018.

  • Girard Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2018 after selling out during the quarter.
  • Girard Partners sold 100 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2018, an estimated $1K.
  • Girard Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2018 and held it in 1 quarter.
  • Girard Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1K in Q3 2018.
  • 239 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.